CN109475563A - 蛋白酶抑制剂的长效医药组合物 - Google Patents

蛋白酶抑制剂的长效医药组合物 Download PDF

Info

Publication number
CN109475563A
CN109475563A CN201680085468.2A CN201680085468A CN109475563A CN 109475563 A CN109475563 A CN 109475563A CN 201680085468 A CN201680085468 A CN 201680085468A CN 109475563 A CN109475563 A CN 109475563A
Authority
CN
China
Prior art keywords
base
carbon atoms
formula
composition
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680085468.2A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·念原·张
梁祥发
陈孟炘
郭桂伶
李安婕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taimed Biologics Inc
Original Assignee
Taimed Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taimed Biologics Inc filed Critical Taimed Biologics Inc
Publication of CN109475563A publication Critical patent/CN109475563A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680085468.2A 2016-05-31 2016-05-31 蛋白酶抑制剂的长效医药组合物 Pending CN109475563A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/035029 WO2017209732A1 (en) 2016-05-31 2016-05-31 A long acting pharmaceutical composition of protease inhibitor

Publications (1)

Publication Number Publication Date
CN109475563A true CN109475563A (zh) 2019-03-15

Family

ID=60478957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680085468.2A Pending CN109475563A (zh) 2016-05-31 2016-05-31 蛋白酶抑制剂的长效医药组合物

Country Status (4)

Country Link
EP (1) EP3463374A4 (ja)
JP (1) JP6704058B2 (ja)
CN (1) CN109475563A (ja)
WO (1) WO2017209732A1 (ja)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060287316A1 (en) * 2005-04-27 2006-12-21 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
CN101405293A (zh) * 2005-11-30 2009-04-08 安布林生物制药公司 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法
CN101460454A (zh) * 2006-05-30 2009-06-17 泰博特克药品有限公司 作为hiv天冬氨酰基蛋白酶抑制剂的赖氨酸相关衍生物
WO2008023273A3 (en) * 2006-07-17 2011-03-03 Ambrilia Biopharma Inc. Method for improving pharmacokinetics
US20160089369A1 (en) * 2006-06-23 2016-03-31 Tibotec Pharmaceuticals Ltd. Aqueous suspensions of tmc278

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060287316A1 (en) * 2005-04-27 2006-12-21 Ambrilia Biopharma Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
CN101405293A (zh) * 2005-11-30 2009-04-08 安布林生物制药公司 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法
CN101460454A (zh) * 2006-05-30 2009-06-17 泰博特克药品有限公司 作为hiv天冬氨酰基蛋白酶抑制剂的赖氨酸相关衍生物
US20160089369A1 (en) * 2006-06-23 2016-03-31 Tibotec Pharmaceuticals Ltd. Aqueous suspensions of tmc278
WO2008023273A3 (en) * 2006-07-17 2011-03-03 Ambrilia Biopharma Inc. Method for improving pharmacokinetics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LALIT KUMAR等: "Nanotechnology: A magic bullet for HIV AIDS treatment", 《ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY》 *
MALAY K. DAS等: "Nano-ART and NeuroAIDS", 《DRUG DELIVERY AND TRANSLATIONAL RESEARCH,SPRINGER》 *

Also Published As

Publication number Publication date
JP6704058B2 (ja) 2020-06-03
EP3463374A1 (en) 2019-04-10
JP2019510002A (ja) 2019-04-11
WO2017209732A1 (en) 2017-12-07
EP3463374A4 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
JP5769762B2 (ja) 治療組成物およびその使用
JP5769763B2 (ja) 治療用組成物およびその使用
AU2013358897B2 (en) Pharmaceutical compositions
US10092523B2 (en) Long acting pharmaceutical compositions
US20040152625A1 (en) Method for improving the pharmacokinetics of an NNRTI
CN109475563A (zh) 蛋白酶抑制剂的长效医药组合物
JPH08507774A (ja) 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用
CA3068212A1 (en) A pharmaceutical nanosuspension for the treatment of hiv infection
JPH10503178A (ja) Ｈｉｖ感染のための組合わせ療法
TWI678203B (zh) 蛋白酶抑制劑之長效醫藥組合物
US10369129B2 (en) Long acting pharmaceutical composition of protease inhibitor
JPH10504036A (ja) Ｈｉｖプロテアーゼ阻害剤の組合わせ体
KR20220161403A (ko) 아리피프라졸 주사가능한 제제의 투여 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190315